AAO Digital GUIDELINES Apps (free trial)

Diabetic Retinopathy

AAO GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/557414

Contents of this Issue

Navigation

Page 9 of 19

8 Management Summary of Management Recommendations Î Screening programs should follow established guidelines. (III, G, S) Î Physicians who care for patients with diabetes, and patients themselves, need to be educated about indications for ophthalmologic referral. (III, G, S) Î Close partnership with the primary care physician is important to make sure that patient care is optimized. (III, G, S) Î People with Type 1 diabetes should have annual screenings for diabetic retinopathy beginning 5 years after the onset of their disease, while those with Type 2 diabetes should have yearly screening for diabetic retinopathy beginning immediately following their diagnosis. (II+, G, S) Î The patient with a normal retinal exam or minimal nonproliferative diabetic retinopathy (NPDR) should be re-examined annually. (III, G, S) Î Referral to an ophthalmologist is required when there is any non- proliferative diabetic retinopathy, proliferative retinopathy, or macular edema. (III, G, S) Î An ophthalmologist who treats patients for macular edema should be familiar with relevant studies and techniques as described in the Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). (III, G, S) Î Patients with retinal microaneurysms and occasional blot hemorrhages or hard exudates should be re-examined within 6–12 months. (III, G, S) Î Patients with mild or moderate NPDR and non-clinically significant macular edema should be re-examined within 3–4 months. (III, G, S) Î Patients with very severe NPDR should be re-examined within 2–4 months. (III, G, S) Î Ophthalmologists should communicate to the primary care physician the ophthalmologic findings and level of retinopathy as well as the need for optimizing metabolic control. (III, G, S) ÎPatients with diabetes may use aspirin for other medical indications without an adverse effect on their risk of diabetic retinopathy. (I++, G, D)

Articles in this issue

Archives of this issue

view archives of AAO Digital GUIDELINES Apps (free trial) - Diabetic Retinopathy